Ligand Pharmaceuticals Incorporated · NASDAQ:LGND
Ligand Pharmaceuticals — SPAC Merger (June 2022)
80 slides from Ligand Pharmaceuticals's SPAC merger presentation, Jun 21, 2022
Slide 1: Analyst Teach-In
Analyst Teach - In June 21, 2022 11 am EDT
Slide 2: Legal Disclaimers
2 LEGAL DISCLAIMERS About this Presentation This presentation is for informational purposes only to assist interested parties in making their own evaluation with respect to a proposed business combination (the Business Combination) between Avista Public Acquisition Corp. II (APAC) and OmniAb, Inc. (
Slide 3: Legal Disclaimers
3 LEGAL DISCLAIMERS Important Information and Where to Find It In connection with the proposed transaction, OmniAb will file a registration statement on Form 10 registering shares of OmniA b c ommon stock and APAC has filed a registration statement on Form S - 4 (File No. 333 - 264525) with the SEC
Slide 4: Welcome
OrnniAb Matt Foehr Leen eS Welcome — 2 . o¢. ‘ os PeGRRRE TR ‘ ee 52. Sap “..* - oe. fe . BS ? iss r , = » ja Ae. : ie Py ° fn Hy hy: a a eae see os 2 “3 ent ’ - ; Sgn a“ > 4 7 ty S. a 3 = s # £ » * . eg ow” . . “
Slide 5: Today's Agenda
5 TODAY’S AGENDA Topic Presenter Slides Intro to OmniAb Matt Foehr 6 - 22 Diverse Antibody Repertoires Bill Harriman, PhD 23 - 35 Screening Technologies and Identification Bob Chen, PhD 36 - 43 Ion Channel Technology and Partnerships Doug Krafte, PhD 44 - 50 Partners and Portfolio Christel Iffland,
Slide 6: Setting the Stage
6 SETTING THE STAGE • Ligand’s proven business model is focused on developing and acquiring technologies that enable the discovery and development of medicines ‒ 140+ partners among pharmaceutical and biotechnology companies ‒ 400+ fully - funded programs in various stages ‒ 1,600+ issued patents wo
Slide 7: Antibodies and Industry Demand
7 0 10 20 30 40 50 60 70 80 Type of Drug Clinical Success Rates (1) Small Molecules 7.5% Antibodies 12.1% Sources: 2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics (La Merie Publishing). Tables of approved mAbs and antibodies in review available at https://ww
Slide 8: Value Proposition
8 The OmniAb discovery platform provides our partners access to the most diverse antibody repertoires and cutting - edge screening technologies to enable discovery of next - generation therapeutics. Value Proposition
Slide 9: Mission
9 Mission Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies . We achieve this by enabling the discovery of high - quality therapeutic candidates and by being the partner of choice for pharma and biotech companies.
Slide 10: OmniAb + Avista: A Combination of Two Leading Life Sciences Franchises
10 OMNIAB + AVISTA A COMBINATION OF TWO LEADING LIFE SCIENCES FRANCHISES Platform Track Record People Source: Company materials and filings. (1) Total of $8 billion equity invested includes ~$3 billion from co - investors / co - sponsors. Total of 42 healthcare companies inclu des transactions at DL
Slide 11: Adding a Leading Drug Discovery Platform to Avista's Pharma Services Portfolio
11 ADDING A LEADING DRUG DISCOVERY PLATFORM TO AVISTA’S PHARMA SERVICES PORTFOLIO Discovery Early - Stage Research & Development Late - Stage Development & Commercialization • Built capabilities and competitive strengths to become partner of choice ‒ BI designed to yield industry’s most diverse sets
Slide 12: Experienced Leadership Team & Board
12 EXPERIENCED LEADERSHIP TEAM & BOARD Carolyn Bertozzi, PhD Board Member Professor of Humanities & Sciences Stanford University Investigator HHMRI Former Board Member Eli Lilly, Advisor to GlaxoSmithKline Founder of multiple companies Sarah Boyce Board Member Chair of HC&C Committee CEO, Avidity Bo
Slide 13: The OmniAb Platform
THE OMNIAB PLATFORM oe a
Slide 14: OmniAb History
14 OMNIAB HISTORY BEST - IN - CLASS PLATFORM BUILT FROM 13+ YEARS OF INVESTMENT AND STRATEGIC ACQUISITIONS Ligand Acquired OMT (OmniAb) Crystal BioScience ( OmniChicken) 2008 2016 2017 2018 2019 2020 OMT Founded Ab Initio (Computationally Powered Antigen Design) xCella Biosciences (Microcapillary Pl
Slide 15: OmniAb's Historical Growth Within Ligand
15 Substantial progress in all phases, increase in discovery programs expected to feed growth in new clinical programs and future approvals Discovery: 231 Preclinical: 11 Phase 1: 18 Phase 2: 2 Phase 3: 2 Registration: 1 Approved : 2 Discovery : 20 Preclinical : 1 OMNIAB’S HISTORICAL GROWTH WITHIN L
Slide 16: Partner Progression
16 PARTNER PROGRESSION SELECT RECENT DEVELOPMENTS SHOW CONTINUED MOMENTUM In Registration Additional Phase 3s Phase 2 Progression Entering Phase 2 • Data from MajesTEC - 1 study published in New England Journal of Medicine , suggest continued deep and durable responses in patients with relapsed and
Slide 17: The OmniAb Platform
17 THE OMNIAB PLATFORM Technology offering addresses critical industry needs and is paired with our highly specialized and efficient operations Create Diverse Pools of High - Quality Naturally Optimized Antibodies Screen Millions of Cells to Find Potential Therapeutic Candidates Further Characterize
Slide 18: The OmniAb Platform
18 THE OMNIAB PLATFORM Technology offering addresses the most critical challenges of antibody discovery
Slide 19: Key Performance Indicators
19 KEY PERFORMANCE INDICATORS • Strong consistent annual growth in key performance indicators ‒ Active Partners (1) : >30% CAGR 2014 through 2021 ‒ Active Programs (2) : >25% CAGR 2016 through 2021 • Highly scalable, with a number of programs performed entirely by partners HIGHLY SCALABLE BUSINESS M
Slide 20: Intellectual Property Advantage
20 INTELLECTUAL PROPERTY ADVANTAGE Antibody Patent Applications Filed by Partners PARTNERS FILING PATENTS ON OMNIAB - DERIVED ANTIBODIES CAN CREATE DIVERSE AND DURABLE ROYALTY STREAMS AND A LENGTHY IP TAIL >60 patent filings by our partners claiming an OmniAb - derived antibody as primary invention,
Slide 21: OmniAb Today – Key Areas of Focus
21 OMNIAB TODAY – KEY AREAS OF FOCUS WE BELIEVE WE ARE WELL - POSITIONED FOR FUTURE GROWTH WHILE WE MAKE AN ENDURING AND SIGNIFICANT IMPACT ON THE INDUSTRY WE LEVERAGE A HIGHLY - SCALABLE BUSINESS WHERE INVESTMENTS IN Partnered Pipeline Development, Expansion and Advancement Expanding the Reach of o
Slide 22: Scientific Leadership Team
22 SCIENTIFIC LEADERSHIP TEAM Phil Leighton, PhD Sr. Director, Molecular Biology Genetic Engineering Lead, Crystal Bioscience and Origen Princeton, UCSF Ellen Collarini, PhD Sr. Director, Cell Biology Crystal Bioscience, Trellis, Roche Univ. Michigan, Univ. College - London Shelley Izquierdo, PhD Sr
Slide 23: Creation of Diverse Antibody Repertoires
Creation of Diverse Antibody Repertoires Bill Harriman, PhD
Slide 24: The OmniAb Platform: Antibody Generation Technologies
24 THE OMNIAB PLATFORM We believe generating large and diverse pools of high - quality antibodies increases the likelihood of discovering the antibody with the most desirable therapeutic characteristics Robust Antibodies for Any Target Bispecific Antibody Generation Cow - inspired Antibodies for Dif
Slide 25: Antigen Design Technology
25 ANTIGEN DESIGN TECHNOLOGY Purified native membrane protein Antigen Expression Full WT, chimeric Mutant, tags Fusion proteins Cloning Purification Reconstitution QC Mammalian Insect Detergent optimization Affinity chromatography Micelles Proteoliposomes Size - exclusion chromatography Radioligand
Slide 26: Why Immunize with Purified, Full-Length Membrane Proteins?
26 WHY IMMUNIZE WITH PURIFIED, FULL - LENGTH MEMBRANE PROTEINS? • Commonly used membrane protein antigens: ‒ Extracellular loop peptides ‒ Non - functional, denatured receptor ‒ DNA • Purified integral membrane proteins: ‒ Have complex epitopes consisting of multiple extracellular loops ‒ Present a
Slide 27: Rodent Platforms
27 RODENT PLATFORMS • Endogenous Ig genes inactivated • Expression of full human V gene diversity • Streamlined conversion into fully human molecule Geurts et al. Science 2009 Ménoret et al. Eur J Immunol 2010 Osborn et al. J. Immunol. 2013 mRNA Human Antibody Light chain loci VL J CL + VJ C VH DH J
Slide 28: OmniChicken: Powered by Evolution
28 P rimordial target gene C hicken orthologue M urine orthologue Human orthologue 300 million years 95 million years OMNICHICKEN Greater evolutionary distance yields greater immunogenicity and more antibody diversity POWERED BY EVOLUTION
Slide 29: HER2 Orthologues
29 HER2 ORTHOLOGUES H uman vs . C hicken (differences in green ) H uman vs . Mouse (differences in pink )
Slide 30: Engineering of Ig Loci
30 ENGINEERING OF IG LOCI Human V’s selected for: • High expression level, stability, ubiquity • High sequence diversity in CDRs • Low sequence diversity in FWs ADAPTATION TO CHICKEN GENE CONVERSION PROCESS CDR - focused diversity G ene conversion Germline VH3 - 23 VK3 - 15 or VL1 - 44 // // // // /
Slide 31: Common Light Chain Platforms for Bispecific Antibodies
31 COMMON LIGHT CHAIN PLATFORMS FOR BISPECIFIC ANTIBODIES STANDARD IGG FORMAT TO DE - RISK DOWNSTREAM DEVELOPMENT † Monospecific IgG Bispecific IgG Rearranged human VK3 - 15 light chain combined with diversifying heavy chain JK2 - 5 Rearranged IgVK3 - 15/JK1 IgKC IgVK3 - 15/JK1 / / Simple reformatti
Slide 32: OmniTaur: Ultralong CDRH3s Create Novel Binding Domains
32 OMNITAUR: ULTRALONG CDRH3S CREATE NOVEL BINDING DOMAINS • Novel structure may enable targeting epitopes unreachable by standard antibodies • Long H3 domains can be expressed on human VH framework, or alone as ~5kD Picobodies Œ UNIQUE STRUCTURAL FEATURES OF ULTRALONG H3 ANTIBODIES CDRH3 Human Cow
Slide 33: OmniTaur mAbs Share a Structural Theme with Bioactive Natural Peptides
33 OMNITAUR MABS SHARE A STRUCTURAL THEME WITH BIOACTIVE NATURAL PEPTIDES RS C IDTIPKSR C TAFQ C KHSMKYRLSF C RKT C GT C Shk peptide S C PDGYRERSD C SNRPA C GTSD CC RVSVFGN C LTT Cow antibody “knob” Natural peptide “Picobody ” mAb Long H3 mAbs potentially combine high biological potency with high
Slide 34: mAb Binding Modes to Ion Channel Kv1.3
34 MAB BINDING MODES TO ION CHANNEL KV1.3 H3 LENGTH IMPACTS TYPES OF MOLECULAR INTERACTION Long H3 mAb binds within pore Nanobodies (~15KD) bind turret loops Selvakumar et al, 2022 doi: https://doi.org/10.1101/2022.04.19.488765
Slide 35: OmniAb Antibody Repertoires
35 OMNIAB ANTIBODY REPERTOIRES Host V genes Structural and immunological features Benefits for therapeutics discovery and development Full human V gene diversity Choice of light chain isotype Diverse V gene usage and mixed genetic backgrounds Widely accessible and flexible workflows Full human V gen
Slide 36: Screening Technology and Antibody Identification
Screening Technology and Antibody Identification Bob Chen, PhD
Slide 37: Discovery Platforms
37 DISCOVERY PLATFORMS Hybridoma Workflow B - cell Workflow Immunization Isolate B - cells Sequence Bioinformatics enrichment optional Single - cell NGS Expression Validation Screen Fusion Technologies enable screening against difficult targets : GPCRs, ion channels and surface antigens Our powerful
Slide 38: Screening Technology: GEM Assay
38 SCREENING TECHNOLOGY: GEM ASSAY GEL ENCAPSULATED MICROENVIRONMENT Izquierdo et al. Microscopy, 2016, 1 - 12 B - cell Target 2 Target 1 Dual bead GEM Cell - based GEM
Slide 39: Screening Technology: xPloration
39 SCREENING TECHNOLOGY: XPLORATION 3 | Recovery & Single - Cell NGS Precise laser - based recovery 1 cell/sec (single - cell mode), single - cell barcoding 2 | Assay + Machine Vision Label - free Bright Field Enzyme Inhibitions Enzymatic Reactions cAMP Signaling 20 hr GFP Reporter Primary Cells 24
Slide 40: 40 40
40 40
Slide 41: Deeper Characterization Identifies New Clonotype Families
41 DEEPER CHARACTERIZATION IDENTIFIES NEW CLONOTYPE FAMILIES • xPloration Œ expands on majority of clonotypes identified by GEM assay • Multiple new clonotype families identified • Next - generation sequencing (NGS) adds support to new clusters and reveals even more diversity Each dot represents an
Slide 42: Leveraging Biological Intelligence with Computational Tools
42 LEVERAGING BIOLOGICAL INTELLIGENCE WITH COMPUTATIONAL TOOLS Biological Intelligence Differentiated sources of antibody sequences In silico developability • Sequence liability assessment • Comparison to clinical antibodies • Structure - based calculations Sequence databases and ML • Customized clo
Slide 43: The OmniAb Platform
43 THE OMNIAB PLATFORM • Data from multi - parameter screening and performance assays used in combination with bioinformatics • NGS h it expansion to identify variant antibodies with improved characteristics • High - throughput epitope binning and kinetics analysis, and target - specific functional
Slide 44: Ion Channel/Transporter Technology Partnerships
Ion Channel/Transporter Technology Partnerships Doug Krafte, PhD
Slide 45: Ion Channels & Transporters
45 ION CHANNELS & TRANSPORTERS • One of the industry’s most experienced teams of ion channel drug - discovery experts; assembled over decades with a current staff of ~ 40 scientists, including bioinformatics • Continuous growth and development of cutting - edge technologies including high - throughp
Slide 46: Ion Channels & Transporters
46 ION CHANNELS & TRANSPORTERS • Voltage - gated ion channel discovery (Nav, Kv, Cav) • Inward rectifier and 2 - pore potassium channels • TRP channels and second messenger - gated channels (i.e., KCa1, 2 & 3.x, Kir6.x) • Ligand - gated ion channels (i.e., GABA A , iGLURx) • Aquaporins EXTENSIVE AND
Slide 47: Existing Publicly-Disclosed Ion Channel Partnerships
47 ION CHANNELS & TRANSPORTERS EXISTING PUBLICLY - DISCLOSED PARTNERSHIPS 2018 2019 2020 2021 Neurodevelopmental Disease Neurodegenerative Disease Cystic Fibrosis 7 POTENTIALLY HIGH - VALUE ION CHANNEL DISCOVERY PROGRAMS WITH 4 PARTNERS Other Neurology Target 1 Target 2 Target 3 Target 1 Target 2 Ta
Slide 48: Where to Next? The Challenge of Targeting Ion Channels
48 WHERE TO NEXT? • Key modulatory domains buried in membrane makes epitope access difficult • Binding itself is not sufficient and understanding functional impact on channel gating is required to develop therapeutics THE CHALLENGE OF TARGETING ANTIBODIES TO ION CHANNELS sensor domain pore domain 90
Slide 49: Next-Gen Solutions for Targeting Ion Channels
49 NEXT - GEN SOLUTIONS SOLVING THE CHALLENGE OF TARGETING ION CHANNELS OmniChicken Leveraging evolutionary distance xPloration Identifying and selecting very rare antibodies Icagen Complex biophysical selection of therapeutic candidates OmniTaur mABs structurally biased for binding deep clefts Bind
Slide 50: Extensive Biological Capabilities for Ion Channels and Transporters
50 THE OMNIAB PLATFORM EXTENSIVE BIOLOGICAL CAPABILITIES FOR ION CHANNELS AND TRANSPORT ERS Proprietary cell lines enable high - speed antigen production Cutting - edge assays facilitate high - throughput screens in GEM and xPloration platforms Proprietary assays leveraged for discovery and characte
Slide 51: Partnered Portfolio Update
Partnered Portfolio Update Christel Iffland, PhD
Slide 52: Select OmniAb Partners
52 SELECT OMNIAB PARTNERS >55 COMPANIES CURRENTLY HAVE ACCESS TO OMNIAB ANTIBODIES
Slide 53: Partner Case Study A: Emerging Biotech
53 THE POWER OF OMNIAB - PARTNER CASE STUDIES • All previously - known antibodies to target could only bind to denatured or fixed form, therefore unsuitable for therapeutic use • Our antigen tech was applied to deliver mg - scale quantities of purified receptor in native conformation for immunizatio
Slide 54: Partner Case Study B: Big Pharma
54 THE POWER OF OMNIAB - PARTNER CASE STUDIES • Human version of target non - immunogenic in other rodents; no titer achieved despite numerous immunization attempts by partner • Genetic knockout of target gene attempted in mice but was lethal • OmniChicken immunization led to robust titers and diver
Slide 55: Partner Case Study C: Established Biotech
55 THE POWER OF OMNIAB - PARTNER CASE STUDIES • Partner needed a flexible, scalable antibody discovery solution to start dozens of new programs every year • Deep collaboration to develop next - generation rodents , which were tested in parallel with active novel programs • OmniAb wholly owns rights
Slide 56: Partner Case Study D: Global Pharma
56 THE POWER OF OMNIAB - PARTNER CASE STUDIES PARTNER D: GLOBAL PHARMA Asia - based global pharma player that is e stablishing a new and substantial presence in antibody space with large investment and expansion of global antibody team • Partner needed OmniAb’s antibody discovery engine to power the
Slide 57: Antibody Repertoire Source Used
57 ANTIBODY REPERTOIRE SOURCE USED ACTIVE PROGRAMS Single OmniAb Source 203 Combination of OmniAb sources 64 DISTRIBUTION OF ANTIBODY REPERTOIRE SOURCES USED TOGETHER FOR BISPECIFICS SOURCE USAGE 24% 62% 14% + + + Combing sources provides partners even more diverse repertoires and new target access
Slide 58: Diverse Drug Formats and Modalities
58 Monoclonal IgG 57% Bispecific (incl. T cell engager) 37% ADC 6% DIVERSE DRUG FORMATS AND MODALITIES PRECLINICAL AND CLINICAL OMNIAB MOLECULES Duobody® (IgG4 exchange) ADAPTIR Œ scFv - Fc - scFv IgG IgG - scFv Antibody - Drug Conjugate Fab - Heavy chain (Knob - in - hole) Variety in the formats an
Slide 59: Partners Continue to Invest Beyond Initial Indication
59 PARTNERS CONTINUE TO INVEST BEYOND INITIAL CLINICAL INDICATION OR GEOGRAPHY • 8 new Phase 2 trials for new treatment settings were started in Q1 2022 • 5 out of 7 new drugs entering Phase 1 in 2021 were bispecific molecules (including four T - cell engagers) STARTED CLINICAL TRIALS (CUMULATIVE, A
Slide 60: OmniAb Clinical and Approved Partner Pipeline
60 OMNIAB CLINICAL AND APPROVED PARTNER PIPELINE TWO APPROVED PRODUCTS AND 23 CLINICAL OMNIAB - DERIVED ANTIBODIES Partner Program Source Animal Area Target Preclinical Phase 1 Phase 2 Phase 3 Registration Approved Zimberelimab OmniRat Oncology PD - 1 Sugemalimab OmniRat Oncology PD - L1 Teclistamab
Slide 61: Financial Review
Financial Review Kurt Gustafson
Slide 62: Transaction Summary
62 TRANSACTION SUMMARY ($ millions) No Redemptions 100% Redemptions Gross Cash Proceeds $265.8 $130.0 Underwriting/Transaction/Other Fees - 28.2 - 28.2 Net Cash $237.6 $101.8 Shares Outstanding 127,681,885 114,681,885 Shares Outstanding includes earnout shares, but excludes OmniAb options, RSUs, PSU
Slide 63: OmniAb Business Model
63 OMNIAB BUSINESS MODEL OUR AGREEMENTS ARE STRUCTURED TO ALIGN ECONOMIC AND SCIENTIFIC INTERESTS WITH OUR PARTNERS License partnerships designed to include: • Technology access and collaboration/service fees • Milestones • Royalties on commercial sales
Slide 64: Illustrative Revenue Profiles for Successful Partnered Programs
64 ILLUSTRATIVE REVENUE PROFILES FOR SUCCESSFUL PARTNERED PROGRAMS OMNIAB PARTICIPATION IS WEIGHTED TOWARDS DOWNSTREAM SUCCESS Target equivalent NPV for all structures Profile A Profile B Flexible transaction structures enable optionality for partners while maintaining value for OmniAb Per - product
Slide 65: Illustrative Antibody Deal Structure
65 ILLUSTRATIVE ANTIBODY DEAL STRUCTURE Year 0 5 10 15 20 25 Collaboration/ Access Fees: ~$1M - $2M Potential IP Extension Notes: Deal Economics have evolved over time. Unique deal structures may also be used (e.g., equity stakes, risk - sharing, buy - in options, etc.). Not representative of Icag
Slide 66: Illustrative Valuation Modeling
Illustrative Valuation Modeling
Slide 67: Modeling OmniAb Value
67 MODELING OMNIAB VALUE • Approved Products & Clinical Pipeline • Existing Discovery/Preclinical Programs • New Programs from New and Existing Partners • Operating Expense 2 Products Approved 23 Clinical - Stage Programs 242 Active Programs in Discovery /Preclinical Development 68 Programs Added in
Slide 68: Published Probability of Success and Timelines for Antibodies
68 PUBLISHED PROBABILITY OF SUCCESS AND TIMELINES FOR ANTIBODIES Probability of Success (1) Cumulative from Program Start Cumulative from Clinical Start Time Range in Stage Discovery 100.0% 100.0% ~4 Years Preclinical 51.0% 51.0% Phase 1 69.0% 35.2% 100.0% Phase 2 54.7% 19.2% 54.7% ~5 - 8 Years Phas
Slide 69: Approved & Clinical-Stage Product Economics
69 APPROVED & CLINICAL - STAGE PRODUCT ECONOMICS Partner Program Development Stage Potential Future Economics Zimberelimab Approved (China) Royalty of 3% Sugemalimab Approved (China) Royalty of 3% Teclistamab Under FDA Review US First Commercial Sale Milestone $25M; EU First Commercial Sale $10M Tir
Slide 70: Applying Standard Success Rates to Standard Timelines
70 APPLYING STANDARD SUCCESS RATES TO STANDARD TIMELINES… 242 Active Research Programs 85 Programs Enter the Clinic 10 Product Approvals 35% POS ~4 yrs 12% POS ~7 - 9 yrs …YIELDS A POTENTIAL SUBSTANTIAL VALUE TO OMNIAB Note: Based on historical industry probabilities of success for antibodies. Actua
Slide 71: New Programs Can Drive Future Growth
71 NEW PROGRAMS CAN DRIVE FUTURE GROWTH Note: Based on historical industry probabilities of success for antibodies. Actual success rates could vary materially. New Program Starts (68 Starts in 2021 ) Programs Enter the Clinic Product Approvals 35% POS ~4 yrs 12% POS ~7 - 9 yrs
Slide 72: Building Blocks of Value
72 BUILDING BLOCKS OF VALUE Collaboration Revenue Existing Approved Products/Clinical Pipeline 242 Research - Stage Programs x POS x Standard Deal Terms New Program Starts x POS x Standard Deal Terms (68 in 2021 and growing) Novel Platform Technologies
Slide 73: Proforma Revenue & Opex
73 PROFORMA REVENUE & OPEX ('000s) 2020 2021 License and milestone Revenue 11,385$ 14,664$ Collaboration Revenue 11,883 20,084 Total revenues 23,268 34,748 Operating costs and expenses: Research and development 24,796 39,232 Selling, general and administrative 10,225 16,947 Amortization of intangibl
Slide 74: Summary
74 SUMMARY • Demand for antibody - based approaches drives the industry’s need for cutting - edge discovery technologies • We maintain a highly - scalable business where investments in and extensions of our differentiated technology are informed by a deep portfolio of partnerships • Our partner pipe
Slide 75: Appendix
APPENDIX =
Slide 76: Zimberelimab: The First Approved OmniRat-Derived Antibody
76 ZIMBERELIMAB THE FIRST APPROVED OMNIRAT - DERIVED ANTIBODY • On August 30, 2021, zimberelimab (GLS - 010), an OmniAb - derived fully human anti - PD - 1 mAb, was approved in China for the treatment of recurrent or refractory classical Hodgkin’s lymphoma ‒ Marked the first approval of an OmniAb -
Slide 77: Sugemalimab: The Second Approved OmniRat-Derived Antibody
77 SUGEMALIMAB THE SECOND APPROVED OMNIRAT - DERIVED ANTIBODY • Fully human, full - length anti - PD - L1 immunoglobulin G4 (IgG4) mAb, which may reduce risk of immunogenicity and toxicity, a unique advantage over similar drugs • Sugemalimab ( Cejemly ® ) was approved in China on June 6, 2022 for un
Slide 78: Teclistamab: Bispecific Antibody for Multiple Myeloma
78 TECLISTAMAB BISPECIFIC ANTIBODY FOR MULTIPLE MYELOMA • Janssen is developing teclistamab, an investigational, fully humanized IgG4, T - cell redirecting, bispecific antibody targeting both BCMA (B - cell maturation antigen) and CD3 ‒ Discovered in part with the OmniAb platform technology (anti -
Slide 79: Sources and Uses; Transaction Overview
79 ($m) Sources Uses APAC Cash $236 Cash to Balance Sheet $250 Avista Minimum Commitment 15 Estimated Transaction Fees 16 Ligand Contribution 15 Total $266 Total $266 75.0% 20.3% 4.7% Ligand Shareholders APAC Shareholders Avista Shares ▪ OmniAb, Inc., an antibody discovery business wholly owned by L
Slide 80: For more information, please visit www.omniab.com
For more information, please visit www.omniab.com